ES2153897T3 - Complejos de inclusion formados por n-morfolino-n-nitrosaminoacetonitrilo y ciclodextrina. - Google Patents
Complejos de inclusion formados por n-morfolino-n-nitrosaminoacetonitrilo y ciclodextrina.Info
- Publication number
- ES2153897T3 ES2153897T3 ES95918104T ES95918104T ES2153897T3 ES 2153897 T3 ES2153897 T3 ES 2153897T3 ES 95918104 T ES95918104 T ES 95918104T ES 95918104 T ES95918104 T ES 95918104T ES 2153897 T3 ES2153897 T3 ES 2153897T3
- Authority
- ES
- Spain
- Prior art keywords
- complexes
- sin
- cyclodextrines
- ions
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NUEVOS COMPLEJOS DE INCLUSION QUE SON ESTABLES EN SU ESTADO SOLIDO DE SIN-1A Y DERIVADOS DE CICLODEXTRIN Y CICLODEXTRINAS Y QUE CONTIENEN TAMBIEN OPCIONALMENTE IONES COMO CATALIZADORES Y ESTABILIZADORES. LOS COMPLEJOS LIBERAN OXIDO NITRICO A TEMPERATURA AMBIENTE AL DISOLVERSE EN AGUA O SISTEMAS ACUOSOS. COMPOSICIONES FARMACEUTICAS ADEMAS DE EQUIPOS QUE CONTIENEN LOS COMPLEJOS. LOS EQUIPOS SE UTILIZAN COMO ESTANDARES DE LIBERACION NO PARA LIBERAR NO EN UNA CANTIDAD PREDECIBLE Y UN INDICE AL DISOLVERSE EN MEDIOS ACUOSOS. PROCESOS PARA LA PREPARACION DE LOS COMPLEJOS SOMETIENDOLOS A UN PH SIN-1 APROPIADO A LA ACCION CATALITICA DE LOS IONES PARA DESPLAZAR EL EQUILIBRIO HACIA LA FORMACION DE SIN-1A EN LA PRESENCIA DE CILCODEXTRINAS O DERIVADOS DE CICLODEXTRINAS CAPACES DE FORMAR COMPLEJOS DE INCLUSION, EN LOS QUE LA SIN-1A FORMADA ES COMPLEJADA INMEDIATAMENTE Y ESTABILIZADA, Y AISLANDO EN EL ESTADO SOLIDO LOS COMPLEJOS NUEVOS OBTENIDOS QUE CONTIENEN IONES OPCIONALMENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9401183A HU218280B (en) | 1994-04-26 | 1994-04-26 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2153897T3 true ES2153897T3 (es) | 2001-03-16 |
Family
ID=10985114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95918104T Expired - Lifetime ES2153897T3 (es) | 1994-04-26 | 1995-04-25 | Complejos de inclusion formados por n-morfolino-n-nitrosaminoacetonitrilo y ciclodextrina. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5698535A (es) |
| EP (1) | EP0705255B1 (es) |
| JP (1) | JP3434828B2 (es) |
| KR (1) | KR960703404A (es) |
| CN (1) | CN1060164C (es) |
| AT (1) | ATE197708T1 (es) |
| AU (1) | AU694219B2 (es) |
| BG (1) | BG61974B1 (es) |
| BR (1) | BR9506155A (es) |
| CA (1) | CA2163539C (es) |
| CZ (1) | CZ316395A3 (es) |
| DE (1) | DE69519463T2 (es) |
| DK (1) | DK0705255T3 (es) |
| ES (1) | ES2153897T3 (es) |
| FI (1) | FI956156A7 (es) |
| GR (1) | GR3035356T3 (es) |
| HR (1) | HRP950249A2 (es) |
| HU (1) | HU218280B (es) |
| IL (1) | IL113491A (es) |
| LT (1) | LT4167B (es) |
| LV (1) | LV11543B (es) |
| MD (1) | MD1419G2 (es) |
| NO (1) | NO311030B1 (es) |
| NZ (1) | NZ285149A (es) |
| PL (1) | PL312183A1 (es) |
| PT (1) | PT705255E (es) |
| RO (1) | RO114449B1 (es) |
| RU (1) | RU2136698C1 (es) |
| SI (1) | SI0705255T1 (es) |
| SK (1) | SK155195A3 (es) |
| WO (1) | WO1995029172A1 (es) |
| YU (1) | YU25995A (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| EP1272531B8 (en) * | 1999-11-12 | 2007-02-14 | Roquette Frˬres | Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| RU2332425C2 (ru) * | 2002-09-06 | 2008-08-27 | Инсёрт Терапьютикс, Инк. | Полимеры на основе циклодекстрина для доставки терапевтических средств |
| BRPI0314042B8 (pt) | 2002-09-06 | 2021-05-25 | Calando Pharmaceuticals Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| WO2004032862A2 (en) * | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| AU2010321533A1 (en) * | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| JP7110360B2 (ja) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | 凍結乾燥方法 |
| CN113614477B (zh) | 2019-03-14 | 2023-04-28 | 泰尔茂比司特生物技术有限公司 | 冷冻干燥装载托盘组件及系统 |
| CN116249522A (zh) * | 2020-07-20 | 2023-06-09 | 深圳迈瑞生物医疗电子股份有限公司 | 一种组合物的血小板解聚用途、解聚试剂及解聚方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780180A (en) | 1971-02-04 | 1973-12-18 | Sandoz Ag | N-substituted amino-n-nitroso-aminoace-tonitriles in the treatment of hypertension |
| US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
| HU212730B (en) * | 1990-03-28 | 1996-10-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them |
| AU668107B2 (en) * | 1991-09-24 | 1996-04-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5389675A (en) * | 1992-03-27 | 1995-02-14 | The United States Of America As Represented By The Department Of Health And Human Services | Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents |
-
1994
- 1994-04-26 HU HU9401183A patent/HU218280B/hu not_active IP Right Cessation
-
1995
- 1995-04-25 MD MD95-0440A patent/MD1419G2/ro unknown
- 1995-04-25 DK DK95918104T patent/DK0705255T3/da active
- 1995-04-25 IL IL11349195A patent/IL113491A/en not_active IP Right Cessation
- 1995-04-25 BR BR9506155A patent/BR9506155A/pt not_active Application Discontinuation
- 1995-04-25 EP EP95918104A patent/EP0705255B1/en not_active Expired - Lifetime
- 1995-04-25 JP JP52720795A patent/JP3434828B2/ja not_active Expired - Lifetime
- 1995-04-25 PL PL95312183A patent/PL312183A1/xx unknown
- 1995-04-25 PT PT95918104T patent/PT705255E/pt unknown
- 1995-04-25 AU AU24159/95A patent/AU694219B2/en not_active Expired
- 1995-04-25 WO PCT/HU1995/000011 patent/WO1995029172A1/en not_active Ceased
- 1995-04-25 YU YU25995A patent/YU25995A/sh unknown
- 1995-04-25 DE DE69519463T patent/DE69519463T2/de not_active Expired - Lifetime
- 1995-04-25 US US08/571,853 patent/US5698535A/en not_active Expired - Fee Related
- 1995-04-25 RU RU96100760A patent/RU2136698C1/ru active
- 1995-04-25 CN CN95190353A patent/CN1060164C/zh not_active Expired - Fee Related
- 1995-04-25 NZ NZ285149A patent/NZ285149A/en unknown
- 1995-04-25 ES ES95918104T patent/ES2153897T3/es not_active Expired - Lifetime
- 1995-04-25 RO RO95-02248A patent/RO114449B1/ro unknown
- 1995-04-25 CA CA002163539A patent/CA2163539C/en not_active Expired - Lifetime
- 1995-04-25 SI SI9530435T patent/SI0705255T1/xx unknown
- 1995-04-25 SK SK1551-95A patent/SK155195A3/sk unknown
- 1995-04-25 KR KR1019950705912A patent/KR960703404A/ko not_active Ceased
- 1995-04-25 AT AT95918104T patent/ATE197708T1/de active
- 1995-04-25 CZ CZ953163A patent/CZ316395A3/cs unknown
- 1995-04-25 HR HRP9401183A patent/HRP950249A2/hr not_active Application Discontinuation
- 1995-12-20 FI FI956156A patent/FI956156A7/fi not_active Application Discontinuation
- 1995-12-22 LV LVP-95-383A patent/LV11543B/en unknown
- 1995-12-22 NO NO19955283A patent/NO311030B1/no not_active IP Right Cessation
- 1995-12-22 LT LT95-133A patent/LT4167B/lt not_active IP Right Cessation
-
1996
- 1996-01-26 BG BG100313A patent/BG61974B1/bg unknown
-
2001
- 2001-02-02 GR GR20010400181T patent/GR3035356T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2153897T3 (es) | Complejos de inclusion formados por n-morfolino-n-nitrosaminoacetonitrilo y ciclodextrina. | |
| AR023836A1 (es) | Metodo y composicion para inhibir la corrosion en los sistemas acuosos | |
| ES2052881T3 (es) | Agentes reductores de la presion sanguinea. | |
| CA2305313A1 (en) | Acylsulfamoylbenzamides, crop protection compositions comprising them, and processes for their preparation | |
| BR0000666A (pt) | Aminas impedidas por grupos n-alcóxi, substituìdas por hidróxi | |
| ES2168737T3 (es) | Inhibidores de la oxido nitrico sintasa. | |
| BR0110801A (pt) | Análogos antitumorais de et-743 | |
| ES2058725T3 (es) | Aplicacion transdermica de 2-amino-6-n-propilamino-4,5,6,7-tetrahidrobenzotiazol. | |
| ES2086529T3 (es) | Sistema transdermico. | |
| ES8206531A1 (es) | Metodo para producir un 1,1-dioxopenicilanoiloximetil 6- (d-a-amino-a-fenilacetamido)penicilanato tosilato hidrato cristalino | |
| ES8700249A1 (es) | Procedimiento para preparar derivados de acido 4-fenil-1,3-dioxan-cis-5-ilalquenoico | |
| IT1244643B (it) | Composizioni di calcestruzzo da spruzzare | |
| PL1628932T3 (pl) | Dodatek hydrofobizujący | |
| ES2094218T3 (es) | Derivados de 2-nitroimidazol, su fabricacion, y agente radiosensibilizante que lo incluye como principio activo. | |
| AR002878A1 (es) | Una formulacion liquida de 1,2-benzoisotiazolin-3-ona y un metodo para prepararla. | |
| ES8505997A1 (es) | Un procedimiento para la preparacion de dihidropiridinas | |
| IT1184428B (it) | Composizione idrogeno assorbente per cavi e elettrici,cavi a fibre ottiche e loro componenti incorporanti detta composizione | |
| ES8200089A1 (es) | Un procedimiento para la preparacion de sales de triarilsul fonio | |
| BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
| WO1999050269A3 (de) | Porphyrine und ihre verwendung als phptosensitizer | |
| ES2161201T1 (es) | Derivado de benzamida, composiciones que contienen dicho derivado y su empleo. | |
| ES2210733T5 (es) | Compuesto detergente. | |
| BR0007275A (pt) | Naftopiranos e fenantropiranos anelados em c5-c6com um grupo bicìclico e composições e matrizes | |
| ES2144862T3 (es) | Masas de moldeo ignifugas termoplasticas con comportamiento a la elaboracion mejorado. | |
| ES2066102T3 (es) | Procedimiento de alcoxilacion catalizado por fosfato de bario. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 705255 Country of ref document: ES |